Sirolimus is an immunosuppressant commonly used in solid organ transplantation as an alternative to corticosteroids or calcineurin inhibitors. Common side effects include hyperlipidemia, arthralgias, and noncardiac peripheral edema. Pulmonary toxicity is increasingly recognized after solid organ transplants [1] [2] [3] . Here we report the first case of sirolimus-associated pneumonitis (SAP) in a peripheral blood stem cell transplant (PBSCT) patient.
A 21-year-old Puerto Rican woman with homozygous sickle cell disease (SCD) had a history of stroke as a child and frequent vaso-occlusive crises while on hydroxyurea. She met inclusion criteria and enrolled in an institutional review board-approved nonmyeloablative peripheral blood stem cell transplant study at the Clinical Center of the National Institutes of Health. She tolerated a low-dose radiation-based conditioning regimen and received a T-replete graft with 10 Â 10 6 per kilogram CD34 1 cells from her HLA-matched sister. She experienced no sickle-related complications, and achieved prompt hematopoietic recovery. She was maintained on sirolimus only, targeting a trough level of 15-20 ng/mL. One year later, she was free of SCD: hemoglobin was 12 g/dL, hemoglobin electrophoresis was stable and compatible with her sickle trait donor, and 100% of peripheral blood CD14/15 leukocytes were of donor origin. She was regularly phlebotomized to correct transfusional iron overload.
Sixteen months after the transplant, she developed cough, dyspnea on exertion, and progressed to debilitating dyspnea over a 4-week interval, but never required supplemental oxygen. There were no antecedent infections, CMV reactivation, acute or chronic GVHD (aGVHD, cGVHD), or other transplant-related complications. Upon admission to evaluate her dyspnea, she was afebrile with normal vital signs; her resting pulse oximetry was 99% to 100% on room air, which decreased to 95% after ambulating 100 meters. Her echocardiogram showed a normal ejection fraction, normal valvular function, and no pulmonary hypertension. Pulmonary function tests showed a severe obstructive and restrictive defect. Computerized tomography (CT) of the chest showed fine, hazy, bilateral, lower lobe infiltrates; no bronchial dilatation or thickening, peribronchial nodules or consolidations were observed. Bronchoalveolar lavage recovered numerous mononuclear and few granulocytic cells; studies for bacteria, atypical organisms, acid fast organisms, fungi, pneumocystis jiroveci (PCP), CMV, and other viruses, were all negative. Sirolimus-associated pneumonitis was suspected, sirolimus was tapered off over 3 days, and oral cyclosporine was initiated; systemic corticosteroid was not administered. Albuterol, ipratroprium, and corticosteroid inhalers were administered. One week later, she had a dramatic response: her subjective dyspnea improved and the distance of her 6-minute walk increased from 195 to 330 meters. She was discharged to home after 2 weeks of hospitalization. Six to 8 months later, her respiratory status, exercise tolerance, PFTs, and CT scans all returned to pretransplant levels ( Figure 1A and B) . Biology
Late noninfectious pulmonary complications following allogeneic PBSCT often require aggressive treatment including corticosteroids and monoclonal antibodies, and are associated with significant morbidity and mortality [4] . Although our patient demonstrated classic features of bronchiolitis obliterans (BO) and bronchiolitis obliterans with organizing pneumonia (BOOP) [5] , her symptoms resolved in 1-2 weeks without intensifying immunosuppression. Her follow-up PFTs steadily improved, and imaging studies showed no indication of relapse or progression, which are uncharacteristic of BO and BOOP.
Although our patient demonstrated both restrictive and obstructive changes, obstructive pulmonary function tests are less commonly observed in SAP [6] . Our patient's underlying SCD may have been a predisposing factor for the observed obstruction, because SCD is commonly associated with asthma [7] [8] [9] . This case also highlights that with the increase use of sirolimus in stem cell transplantation [10] , SAP may be increasingly recognized as in solid-organ recipients. Furthermore, the clinical presentation may differ in this setting. Finally, sirolimus withdrawal can be utilized as a diagnostic test before committing to long-term aggressive corticosteroid and/or monoclonal antibody therapies.
